161 related articles for article (PubMed ID: 31308554)
1. Combinatorial mutagenesis en masse optimizes the genome editing activities of SpCas9.
Choi GCG; Zhou P; Yuen CTL; Chan BKC; Xu F; Bao S; Chu HY; Thean D; Tan K; Wong KH; Zheng Z; Wong ASL
Nat Methods; 2019 Aug; 16(8):722-730. PubMed ID: 31308554
[TBL] [Abstract][Full Text] [Related]
2. Developing Heritable Mutations in Arabidopsis thaliana Using a Modified CRISPR/Cas9 Toolkit Comprising PAM-Altered Cas9 Variants and gRNAs.
Yamamoto A; Ishida T; Yoshimura M; Kimura Y; Sawa S
Plant Cell Physiol; 2019 Oct; 60(10):2255-2262. PubMed ID: 31198958
[TBL] [Abstract][Full Text] [Related]
3. A highly specific SpCas9 variant is identified by in vivo screening in yeast.
Casini A; Olivieri M; Petris G; Montagna C; Reginato G; Maule G; Lorenzin F; Prandi D; Romanel A; Demichelis F; Inga A; Cereseto A
Nat Biotechnol; 2018 Mar; 36(3):265-271. PubMed ID: 29431739
[TBL] [Abstract][Full Text] [Related]
4. In-depth assessment of the PAM compatibility and editing activities of Cas9 variants.
Zhang W; Yin J; Zhang-Ding Z; Xin C; Liu M; Wang Y; Ai C; Hu J
Nucleic Acids Res; 2021 Sep; 49(15):8785-8795. PubMed ID: 34133740
[TBL] [Abstract][Full Text] [Related]
5. [The Development of SpCas9 Variants with High Specificity and Efficiency Based on the HH Theory].
Wang GH; Wang CM; Wu XJ; Chu T; Huang DW; Li J
Mol Biol (Mosk); 2024; 58(1):157-159. PubMed ID: 38943587
[TBL] [Abstract][Full Text] [Related]
6. Identification and Analysis of Small Molecule Inhibitors of CRISPR-Cas9 in Human Cells.
Yang Y; Li D; Wan F; Chen B; Wu G; Li F; Ren Y; Liang P; Wan J; Songyang Z
Cells; 2022 Nov; 11(22):. PubMed ID: 36429003
[TBL] [Abstract][Full Text] [Related]
7. DNA targeting by Clostridium cellulolyticum CRISPR-Cas9 Type II-C system.
Fedorova I; Arseniev A; Selkova P; Pobegalov G; Goryanin I; Vasileva A; Musharova O; Abramova M; Kazalov M; Zyubko T; Artamonova T; Artamonova D; Shmakov S; Khodorkovskii M; Severinov K
Nucleic Acids Res; 2020 Feb; 48(4):2026-2034. PubMed ID: 31943070
[TBL] [Abstract][Full Text] [Related]
8. SMOOT libraries and phage-induced directed evolution of Cas9 to engineer reduced off-target activity.
Cerchione D; Loveluck K; Tillotson EL; Harbinski F; DaSilva J; Kelley CP; Keston-Smith E; Fernandez CA; Myer VE; Jayaram H; Steinberg BE
PLoS One; 2020; 15(4):e0231716. PubMed ID: 32298334
[TBL] [Abstract][Full Text] [Related]
9. Structural insights into a high fidelity variant of SpCas9.
Guo M; Ren K; Zhu Y; Tang Z; Wang Y; Zhang B; Huang Z
Cell Res; 2019 Mar; 29(3):183-192. PubMed ID: 30664728
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis for the PAM expansion and fidelity enhancement of an evolved Cas9 nuclease.
Chen W; Zhang H; Zhang Y; Wang Y; Gan J; Ji Q
PLoS Biol; 2019 Oct; 17(10):e3000496. PubMed ID: 31603896
[TBL] [Abstract][Full Text] [Related]
11. High-throughput analysis of the activities of xCas9, SpCas9-NG and SpCas9 at matched and mismatched target sequences in human cells.
Kim HK; Lee S; Kim Y; Park J; Min S; Choi JW; Huang TP; Yoon S; Liu DR; Kim HH
Nat Biomed Eng; 2020 Jan; 4(1):111-124. PubMed ID: 31937939
[TBL] [Abstract][Full Text] [Related]
12. Engineered dual selection for directed evolution of SpCas9 PAM specificity.
Goldberg GW; Spencer JM; Giganti DO; Camellato BR; Agmon N; Ichikawa DM; Boeke JD; Noyes MB
Nat Commun; 2021 Jan; 12(1):349. PubMed ID: 33441553
[TBL] [Abstract][Full Text] [Related]
13. Engineered CRISPR-Cas9 nucleases with altered PAM specificities.
Kleinstiver BP; Prew MS; Tsai SQ; Topkar VV; Nguyen NT; Zheng Z; Gonzales AP; Li Z; Peterson RT; Yeh JR; Aryee MJ; Joung JK
Nature; 2015 Jul; 523(7561):481-5. PubMed ID: 26098369
[TBL] [Abstract][Full Text] [Related]
14. Systematic in vitro specificity profiling reveals nicking defects in natural and engineered CRISPR-Cas9 variants.
Murugan K; Suresh SK; Seetharam AS; Severin AJ; Sashital DG
Nucleic Acids Res; 2021 Apr; 49(7):4037-4053. PubMed ID: 33744974
[TBL] [Abstract][Full Text] [Related]
15. Potential high-frequency off-target mutagenesis induced by CRISPR/Cas9 in Arabidopsis and its prevention.
Zhang Q; Xing HL; Wang ZP; Zhang HY; Yang F; Wang XC; Chen QJ
Plant Mol Biol; 2018 Mar; 96(4-5):445-456. PubMed ID: 29476306
[TBL] [Abstract][Full Text] [Related]
16. Rationally engineered Cas9 nucleases with improved specificity.
Slaymaker IM; Gao L; Zetsche B; Scott DA; Yan WX; Zhang F
Science; 2016 Jan; 351(6268):84-8. PubMed ID: 26628643
[TBL] [Abstract][Full Text] [Related]
17. Continuous evolution of SpCas9 variants compatible with non-G PAMs.
Miller SM; Wang T; Randolph PB; Arbab M; Shen MW; Huang TP; Matuszek Z; Newby GA; Rees HA; Liu DR
Nat Biotechnol; 2020 Apr; 38(4):471-481. PubMed ID: 32042170
[TBL] [Abstract][Full Text] [Related]
18. PAM-flexible Engineered FnCas9 variants for robust and ultra-precise genome editing and diagnostics.
Acharya S; Ansari AH; Kumar Das P; Hirano S; Aich M; Rauthan R; Mahato S; Maddileti S; Sarkar S; Kumar M; Phutela R; Gulati S; Rahman A; Goel A; Afzal C; Paul D; Agrawal T; Pulimamidi VK; Jalali S; Nishimasu H; Mariappan I; Nureki O; Maiti S; Chakraborty D
Nat Commun; 2024 Jun; 15(1):5471. PubMed ID: 38942756
[TBL] [Abstract][Full Text] [Related]
19. Shortening the sgRNA-DNA interface enables SpCas9 and eSpCas9(1.1) to nick the target DNA strand.
Fan R; Chai Z; Xing S; Chen K; Qiu F; Chai T; Qiu JL; Zhang Z; Zhang H; Gao C
Sci China Life Sci; 2020 Nov; 63(11):1619-1630. PubMed ID: 32592086
[TBL] [Abstract][Full Text] [Related]
20. Enhanced proofreading governs CRISPR-Cas9 targeting accuracy.
Chen JS; Dagdas YS; Kleinstiver BP; Welch MM; Sousa AA; Harrington LB; Sternberg SH; Joung JK; Yildiz A; Doudna JA
Nature; 2017 Oct; 550(7676):407-410. PubMed ID: 28931002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
